• OPEN AN ACCOUNT
Indian Indices
Sensex
73,123.83 -125.56
( -0.17%)
Global Indices
Nasdaq
52,230.09 -658.89
(-1.25%)
Dow Jones
7,644.13 -40.30
(-0.52%)
Hang Seng
62,584.98 -322.86
(-0.51%)
Nikkei 225
10,670.63 -54.40
(-0.51%)
Forex
USD-INR
94.61 0.10
(0.11%)
EUR-INR
106.18 0.08
(0.07%)
GBP-INR
126.70 0.19
(0.15%)
JPY-INR
0.60 0.00
(0.70%)

EQUITY - MARKET SCREENER

Kewal Kiran Clothing Ltd
Industry :  Textiles - Products
BSE Code
ISIN Demat
Book Value()
532732
INE401H01017
150.1548085
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
KKCL
19.03
2582.4
EPS(TTM)
Face Value()
Div & Yield %
22.02
10
0.48
 

Caplin Point Lab declines after arm receives form-485 with 10 observations from USFDA
Aug 24,2026
The inspection was carried out from 13 August 2026 to 21 August 2026. At the conclusion of the inspection, the company received Form 483 containing 10 observations from US Food and Drug Administration (USFDA).

The company said that the observations were procedural in nature and did not pertain to data integrity. It also stated that none of the observations were repeat observations.

Caplin Point Laboratories is a fully integrated pharmaceutical company with a strong presence in Latin America. The company’s consolidated net profit jumped 18.79% YoY to Rs 176.91 crore in Q1 FY27. Net sales increased 19.63% to Rs 610.36 crore in Q1 FY27 from Rs 510.22 crore in Q1 FY26.